Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Keywords

DulaglutideMedicineType 2 diabetesInternal medicineClinical endpointPlaceboPopulationMyocardial infarctionDiabetes mellitusStroke (engine)Adverse effectSemaglutideRandomized controlled trialPhysical therapyExenatideLiraglutideEndocrinology

Affiliated Institutions

Related Publications

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Stephen D. Wiviott , Itamar Raz , Marc P. Bonaca +17 more

In patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease, treatment with dapagliflozin did not result in a higher or lower rate of MAC...

2018 New England Journal of Medicine 5890 citations

Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.

R B Sleight , Peter Sleight , Sarah Parish +3 more

17,187 patients entering 417 hospitals up to 24 hours (median 5 hours) after the onset of suspected acute myocardial infarction were randomised, with placebo control, between: (...

1988 PubMed 2873 citations

Blood Pressure Lowering in Type 2 Diabetes

Connor A. Emdin , Kazem Rahimi , Bruce Neal +3 more

Among patients with type 2 diabetes, BP lowering was associated with improved mortality and other clinical outcomes with lower RRs observed among those with baseline BP of 140 m...

2015 JAMA 827 citations

Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): Effects on mortality at 1 year

Klas Malmberg , Lars Rydén , Suad Efendić +5 more

1995 Journal of the American College of Ca... 1568 citations

Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus

K. Malmberg

Insulin-glucose infusion followed by intensive subcutaneous insulin in diabetic patients with acute myocardial infarction improves long term survival, and the effect seen at one...

1997 BMJ 1299 citations

Publication Info

Year: 2019
Type: article
Volume: 394
Issue: 10193
Pages: 121-130
Citations: 2683
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2683

OpenAlex

Cite This

APA Style

                            
                                
                                    Hertzel C. Gerstein, 
                                
                                    Helen M. Colhoun, 
                                
                                    Gilles R. Dagenais
                                
                                et al.
                            
                            (2019). 
                            Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. 
                            The Lancet
                            , 394
                            (10193)
                            , 121-130.
                            https://doi.org/10.1016/s0140-6736(19)31149-3
                        

Identifiers

DOI: 10.1016/s0140-6736(19)31149-3